Abstract |
We evaluated the effect of urokinase on pulmonary microthrombi formation of the donor lung using a canine cadaver left lung allotransplantation model. Donor animals were sacrificed with an intravenous injection of potassium chloride without heparinization and were divided into three groups. In group 1 (n = 6), cadavers were left at room temperature for 1 hour, and lung retrieval was then performed after flushing the lung block with low potassium-dextran-glucose solution. Donor lungs were stored for 3 hours at 8 degrees C. In group 2 (n = 6), donor lungs were treated as in group 1 except that the cadavers were left at room temperature for 2 hours instead of 1 hour before lung retrieval. In group 3 (n = 6), donor lungs were treated as in group 2 except that high-dose urokinase (120,000 IU) was injected into the main pulmonary artery after flushing with low- potassium- dextrose- glucose solution. In all groups after left lung transplantation, the right pulmonary artery was ligated, and recipient animals were followed up for 6 hours after reperfusion. The fibrin degradation product level in the donor lung tissue was also measured. All recipient animals in group 1 survived the 6-hour observation period with excellent gas exchange and stable hemodynamics. Group 3 had significantly better gas exchange than group 2 and similar cardiopulmonary function as group 1. The fibrin degradation product level in the donor lungs before transplantation was significantly higher in group 3 than in group 2.(ABSTRACT TRUNCATED AT 250 WORDS)
|
Authors | Y Umemori, H Date, K Uno, M Aoe, A Ando, N Shimizu |
Journal | The Annals of thoracic surgery
(Ann Thorac Surg)
Vol. 59
Issue 6
Pg. 1513-8
(Jun 1995)
ISSN: 0003-4975 [Print] Netherlands |
PMID | 7771833
(Publication Type: Journal Article)
|
Chemical References |
- Fibrin Fibrinogen Degradation Products
- Urokinase-Type Plasminogen Activator
|
Topics |
- Animals
- Disease Models, Animal
- Dogs
- Fibrin Fibrinogen Degradation Products
(analysis)
- Injections, Intra-Arterial
- Lung Transplantation
(adverse effects, methods)
- Pulmonary Artery
- Pulmonary Embolism
(drug therapy)
- Pulmonary Gas Exchange
- Tissue and Organ Procurement
(methods)
- Transplantation, Homologous
(methods)
- Urokinase-Type Plasminogen Activator
(therapeutic use)
|